Editorial: Preventing and treating liver diseases: medicinal and food plants, their metabolites as potential options
Open Access
- 18 March 2025
- journal article
- editorial
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1577547
Abstract
Liver disease is seriously endangering human health in the world. It has become the leading cause of death in the word (Israelsen et al., 2024). The presence and progression of liver fibrosis led by hepatic inflammation is the main predictor of liver-related death across the entire spectrum of steatotic liver diseases (Taru et al., 2024). A combination of recent advancements of widely available biomarkers for early detection of liver fibrosis together with considerable advancements in therapeutic interventions offer the possibility to reduce morbidity and mortality in patients with liver disease (Dabrowska et al., 2024). Thus, it is urgent to find safe and effective drugs to treat liver diseases. The medicinal and food plants have unique advantages in terms of safety and compliance, which have always been an important source for finding new hepatoprotective drugs (Xu et al., 2024). Consequently, the discovery of new hepatoprotective natural products from medicinal and food plants is of great practical significance for the development of new hepatoprotective drugs, which has the advantages of safety, multi-targets, and multi-pathways. We are deeply privileged to compile this research topic of Frontiers in Pharmacology dedicated to "preventing and treating liver diseases: medicinal and food plants, their metabolites as potential options".The study by Han et al. discussed about the effects of a low-dose (0.6 g/kg) and high-dose (1.2 g/kg) of zhuyu pill on a cholestasis rat model induced by naphthyl isothiocyanate (50 mg/kg). In this study, serum biochemistry and histopathology results were used to evaluate the therapeutic effect of zhuyu pill, and mRNA-Seq analysis was performed and verified using real-time uorescence quantitative PCR.The GO, KEGG, and GSEA analyses were integrated to identify the mechanism by which Zhuyu pill impacted cholestatic rats.It was found that zhuyu pill significantly improved abnormal changes in the biochemical blood indexes and liver histopathology of cholestasis rats, regulated pathways related to bile and lipid metabolism, including fatty acid metabolism, retinol metabolism, and steroid hormone biosynthesis, and alleviated inflammation, cholestasis, and lipid metabolism disorders.Relative expression of the essential genes Cyp2a1, Ephx2, Acox2, Cyp1a2, Cyp2c11, and Sult2a1 was verified by qRT-PCR and showed the same trend as mRNA-seq analysis (Han et al., 2023). Therefore, zhuyu pill has a significant anti-cholestatic effect by regulating bile metabolism and lipid metabolism related pathways. These findings indicate that zhuyu pill is a novel and promising prospect for treating cholestasis.Rutaecarpine is a natural pentacyclic indolopyridoquinazolinone alkaloid, which is isolated from Evodia rutaecarpa for the first time. It is used for treating a variety of ailments, including headaches, gastrointestinal disorders, postpartum hemorrhage, amenorrhea, difficult menstruation, and other diseases. Li et al. made a comprehensive description of Rutaecarpine derivatives by focusing on their diverse biological activities. In this review, the modification of Rutaecarpine aimed at seeking its derivatives with better physicochemical properties and more potency had been extensively studied. These derivatives exhibited diverse pharmacological activities, including anti-inflammatory, anti-atherogenic, anti-Alzheimer's disease, anti-tumor, and anti-fungal activities via a variety of mechanisms, such as inhibiting cyclooxygenase-2, acetylcholine, phosphodiesterase 4B, phosphodiesterase 5, or topoisomerases (Li et al., 2023). This review gave an insight into the biological activities of Rutaecarpine derivatives and encourage further exploration of Rutaecarpine.Nawaz et al. reviewed therapeutic approaches for chronic hepatitis C. In this review, he critically assesseed the landscape of hepatitis C virus treatment, drawing parallels between traditional interferon/ribavirin therapy historically pivotal in hepatitis C virus management and herbal approaches rooted in traditional and complementary medicine. This review made a comprehensive understanding of the diverse hepatitis C virus genome, its natural variations, pathogenesis, and the impact of dietary, social, environmental, and economic factors (Nawaz et al., 2024). This review primarily focused on the intricate nature of hepatitis C virus genomes and explored the potential of botanical drugs in both preventing and treating hepatitis C virus infections.Feng et al. used meta-analysis to search relevant preclinical references from multiple databases. Statistical analysis was conducted using STATA, which included the use of 3D maps and radar charts to display the effects of matrine dosage and frequency on hepatoprotection and hepatotoxicity. The results demonstrated that matrine had bidirectional effects on ALT and AST levels, and it also regulated SOD, MDA, TG, TC, IL-6, TNF-α, and CAT levels. Based on comprehensive three-dimensional analysis, the optimal bidirectional effective dosage of matrine ranged from 10 to 69.1 mg/kg. However, it demonstrated high liver protection and low toxicity at a dose of 20-30 mg/kg/d for 0.02-0.86 weeks. The molecular docking analysis revealed the interaction between MT and SERCA as well as SREBP-SCAP complexes. Matrine could alter Ca 2+ homeostasis in liver injury via multiple pathways, including the SREBP1c/SCAP, Notch/RBP-J/HES1, IκK/NF-κB, and Cul3/Rbx1/Keap1/Nrf2 (Feng et al., 2024).The pericarp of Herpetospermum pedunculosum has traditionally been used for treating jaundice and hepatitis. Liu et al. characterized the total cucurbitacins extracted from H. pedunculosum and evaluated their hepatoprotective potential.Molecular networking based on UHPLC-MS/MS identified cucurbitacin B, isocucurbitacin B, and cucurbitacin E as the major components in total cucurbitacins, comprising 70.3%, 26.1%, and 3.6% as determined by RP-HPLC, respectively. Total cucurbitacins treatment...Keywords
This publication has 6 references indexed in Scilit:
- Steatotic liver diseaseThe Lancet, 2024
- The Impact of Liver Failure on the Immune SystemInternational Journal of Molecular Sciences, 2024
- Inflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammationJournal of Hepatology, 2024
- Medicinal and edible polysaccharides from ancient plants: extraction, isolation, purification, structure, biological activity and market trends of sea buckthorn polysaccharidesFood & Function, 2024
- Efficacy of Forsythia suspensa (Thunb.) Vahl on mouse and rat models of inflammation-related diseases: a meta-analysisFrontiers in Pharmacology, 2024
- Promising derivatives of rutaecarpine with diverse pharmacological activitiesFrontiers in Chemistry, 2023